Patents by Inventor Claire Dobson
Claire Dobson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11845791Abstract: The present disclosure is directed to human GDF-15-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect human GDF-15 and/or in methods of treating cancer or body weight loss, including cachexia, associated with over-expression of human GDF-15.Type: GrantFiled: March 7, 2022Date of Patent: December 19, 2023Assignee: MEDIMMUNE, LLCInventors: Claire Dobson, Fiona Cusdin, Darren Schofield, Peter Cariuk, Elaine Hurt, Margareta Ek, Carina Johansson, Jenny Sandmark
-
Publication number: 20230242639Abstract: The present disclosure provides antibodies and antigen-binding fragments capable of binding PAR2. In some embodiments, the anti-PAR2 antibodies or antigen-binding fragments thereof bind PAR2 in a pH-dependent manner. The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.Type: ApplicationFiled: February 7, 2023Publication date: August 3, 2023Inventors: Claire DOBSON, Richard WILLIAMS, Ian GURRELL, Sadhana PODICHETTY, David FAIRMAN, Peter THORNTON, Philip NEWTON
-
Patent number: 11591389Abstract: The present disclosure provides antibodies and antigen-binding fragments capable of binding PAR2. In some embodiments, the anti-PAR2 antibodies or antigen-binding fragments thereof bind PAR2 in a pH-dependent manner. The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.Type: GrantFiled: September 29, 2020Date of Patent: February 28, 2023Assignee: MEDIMMUNE LIMITEDInventors: Claire Dobson, Richard Williams, Ian Gurrell, Sadhana Podichetty, David Fairman, Peter Thornton, Philip Newton
-
Publication number: 20220281965Abstract: The present disclosure is directed to human GDF-15-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect human GDF-15 and/or in methods of treating cancer or body weight loss, including cachexia, associated with over-expression of human GDF-15.Type: ApplicationFiled: March 7, 2022Publication date: September 8, 2022Inventors: Claire DOBSON, Fiona CUSDIN, Darren SCHOFIELD, Peter CARIUK, Elaine HURT, Margareta EK, Carina JOHANSSON, Jenny SANDMARK
-
Publication number: 20210061905Abstract: The present disclosure provides antibodies and antigen-binding fragments capable of binding PAR2. In some embodiments, the anti-PAR2 antibodies or antigen-binding fragments thereof bind PAR2 in a pH-dependent manner. The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.Type: ApplicationFiled: September 29, 2020Publication date: March 4, 2021Inventors: Claire Dobson, Richard Williams, Ian Gurrell, Sadhana Podichetty, David Fairman, Peter Thornton, Philip Newton
-
Patent number: 10836822Abstract: The present disclosure provides antibodies and antigen-binding fragments capable of binding PAR2. In some embodiments, the anti-PAR2 antibodies or antigen-binding fragments thereof bind PAR2 in a pH-dependent manner. The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.Type: GrantFiled: March 16, 2018Date of Patent: November 17, 2020Assignee: MedImmune LimitedInventors: Claire Dobson, Richard Williams, Ian Gurrell, Sadhana Podichetty, David Fairman, Peter Thornton, Philip Newton
-
Publication number: 20200247885Abstract: The invention provides antibodies that specifically bind a P2X4 polypeptide and modulate P2X4 channel activity, recombinant P2X4 polypeptides and methods for generating such polypeptides, as well as compositions and methods for generating anti-P2X4 antibodies, and methods of using P2X4 antibodies for the treatment of neuropathic pain and other indications.Type: ApplicationFiled: April 6, 2020Publication date: August 6, 2020Inventors: Wendy A. WILLIAMS, Clare JONES, James BUTTON, John LINLEY, Harm Jan SNIJDER, Ling HUANG, Yoko SHIBATA, Sudharsan SRIDHARAN, Maria GROVES, Claire DOBSON
-
Patent number: 10654926Abstract: The invention provides antibodies that specifically bind a P2X4 polypeptide and modulate P2X4 channel activity, recombinant P2X4 polypeptides and methods for generating such polypeptides, as well as compositions and methods for generating anti-P2X4 antibodies, and methods of using P2X4 antibodies for the treatment of neuropathic pain and other indications.Type: GrantFiled: May 2, 2015Date of Patent: May 19, 2020Assignee: MedImmune LimitedInventors: Wendy A Williams, Clare Jones, James Button, John Linley, Harm Jan Snijder, Ling Huang, Yoko Shibata, Sudharsan Sridharan, Maria Groves, Claire Dobson
-
Publication number: 20180305450Abstract: The present disclosure provides antibodies and antigen-binding fragments capable of binding PAR2. In some embodiments, the anti-PAR2 antibodies or antigen-binding fragments thereof bind PAR2 in a pH-dependent manner. The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.Type: ApplicationFiled: March 16, 2018Publication date: October 25, 2018Inventors: Claire Dobson, Richard Williams, Ian Gurrell, Sadhana Podichetty, David Fairman, Peter Thornton, Philip Newton
-
Publication number: 20170166634Abstract: The invention provides antibodies that specifically bind a P2X4 polypeptide and modulate P2X4 channel activity, recombinant P2X4 polypeptides and methods for generating such polypeptides, as well as compositions and methods for generating anti-P2X4 antibodies, and methods of using P2X4 antibodies for the treatment of neuropathic pain and other indications.Type: ApplicationFiled: May 2, 2015Publication date: June 15, 2017Applicant: Medimmune LimitedInventors: Wendy A WILLIAMS, Clare JONES, James BUTTON, John LINLEY, Harm Jan SNIJDER, Ling HUANG, Yoko SHIBATA, Sudharsan SRIDHARAN, Maria GROVES, Claire DOBSON
-
Patent number: 9255144Abstract: The present invention provides human, humanized and/or chimeric antibodies as well as fragments, derivatives/conjugates and compositions thereof with a specific binding affinity for interleukin-18. The invention includes the use of these antibodies for diagnosing and treating diseases associated with increased IL-18 activity, the latter in the form of a pharmaceutical composition.Type: GrantFiled: December 20, 2011Date of Patent: February 9, 2016Assignee: MedImmune LimitedInventors: Claire Dobson, Steven Lane, Philip Newton, Martin Schwickart, Ann-Charlott Steffen
-
Publication number: 20140004128Abstract: The present invention provides human, humanized and/or chimeric antibodies as well as fragments, derivatives/conjugates and compositions thereof with a specific binding affinity for interleukin-18. The invention includes the use of these antibodies for diagnosing and treating diseases associated with increased IL-18 activity, the latter in the form of a pharmaceutical composition.Type: ApplicationFiled: December 20, 2011Publication date: January 2, 2014Applicant: Medimmune LimitedInventors: Claire Dobson, Steven Lane, Philip Newton, Martin Schwickart, Ann-Charlott Steffen
-
Patent number: 8389704Abstract: This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.Type: GrantFiled: February 15, 2008Date of Patent: March 5, 2013Assignee: MedImmune LimitedInventors: Duncan Cochrane, Suzanne Cohen, Louise Claire Dobson, Fredick Per-Olof Eriksson, David Phillip Monk, Karin Von-Wachenfeldt
-
Publication number: 20110212084Abstract: This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.Type: ApplicationFiled: February 15, 2008Publication date: September 1, 2011Applicants: ASTRAZENECA AB, MEDIMMUNE LIMITEDInventors: Duncan Cochrane, Suzanne Cohen, Louise Claire Dobson, Fredick Per-Olof Eriksson, David Phillip Monk, Karin Von-Wachenfeldt
-
Publication number: 20100150904Abstract: This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.Type: ApplicationFiled: February 15, 2008Publication date: June 17, 2010Applicant: AstraZeneca ABInventors: Duncan Cochrane, Suzanne Cohen, Louise Claire Dobson, Fredick Per-Olof Eriksson, David Phillip Monk, Karin Von-Wachenfeldt
-
Publication number: 20090226429Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.Type: ApplicationFiled: January 18, 2008Publication date: September 10, 2009Applicant: Human Genome Sciences, Inc.Inventors: Theodora W. Salcedo, Steven M. Ruben, Craig A. Rosen, Vivian R. Albert, Claire Dobson, Tristan Vaughan
-
Patent number: 7361341Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.Type: GrantFiled: March 29, 2006Date of Patent: April 22, 2008Assignee: Human Genome Sciences, Inc.Inventors: Theodora W. Salcedo, Steven M. Ruben, Craig A. Rosen, Vivian R. Albert, Claire Dobson, Tristan Vaughan
-
Patent number: 7348003Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.Type: GrantFiled: November 12, 2004Date of Patent: March 25, 2008Assignee: Human Genome Sciences, Inc.Inventors: Theodora W. Salcedo, Steven M. Ruben, Craig A. Rosen, Vivian R. Albert, Claire Dobson, Tristan Vaughan
-
Patent number: 7064189Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.Type: GrantFiled: May 7, 2002Date of Patent: June 20, 2006Assignee: Human Genome Sciences, Inc.Inventors: Theodora Salcedo, Steven M. Ruben, Craig A. Rosen, Vivian R. Albert, Claire Dobson, Tristan Vaughan
-
Publication number: 20030190685Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.Type: ApplicationFiled: May 7, 2002Publication date: October 9, 2003Applicant: Human Genome Sciences, Inc.Inventors: Theodora Salcedo, Steven M. Ruben, Craig A. Rosen, Vivian R. Albert, Claire Dobson, Tristan Vaughan